Carcinoid Syndrome - Prognosis

Prognosis

Prognosis varies from individual to individual. It ranges from a 95% 5 year survival for localized disease to an 80% 5 year survival for those with liver metastases. The average survival time from the start of octreotide treatment has increased to about 12 years.

Read more about this topic:  Carcinoid Syndrome